Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Metabolomics Kit Enables Use with Specialized Mass Spectrometer

By BiotechDaily International staff writers
Posted on 26 Mar 2013
Image: The new “AbsoluteIDQ p150” metabolomics kit (Photo courtesy of Biocrates).
Image: The new “AbsoluteIDQ p150” metabolomics kit (Photo courtesy of Biocrates).
A state-of-the-art metabolomics-based research kit has been specially designed for use with a triple stage quadrupole mass spectrometer, enabling additional laboratories to use such kits.

Biocrates Life Sciences AG (Innsbruck, Austria) introduced “AbsoluteIDQ p150,” the new edition of its well-established line of metabolomics-based research kits. The kit has been available for use with AB Sciex and Waters mass spectrometry systems, and has now been designed to also run on Thermo Scientific’s “TSQ Vantage” Triple Stage Quadrupole Mass Spectrometer, enabling more research labs to harness the power of targeted metabolite quantification with a ready-to-use kit system. Combined with a robust new ion source, second-generation ion optics, and hyperbolic quadrupoles, the “TSQ Vantage” mass spectrometer delivers both higher sensitivity and lower chemical noise.

AbsoluteIDQ p150 provides extensive metabolic information from a single targeted assay, quantifying 158 metabolites using a FIA-MS/MS method. It features the proprietary “MetIDQ” software, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice with a cost-effective solution to measure endogenous metabolites under quality-controlled conditions in a researcher’s own laboratory. The Biocrates AbsoluteIDQ kits have been successfully applied in many different areas, including oncology, endocrinology, diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research. Biocrates mass spectrometry-based, standardized metabolomic kits provide multiplexing potential and superior accuracy and precision.

Related Links:
Biocrates




Channels

Genomics/Proteomics

view channel
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).

Double Targeting Approach Increases Potential for Cancer Treatment with Oncolytic Viruses

Cancer researchers have used a double targeting approach to direct oncolytic viruses specifically to tumor cells where they reproduce until the cancer cells burst, releasing more viruses to infect and... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.